Literature DB >> 28488614

Safety and efficacy of therapeutic membrane plasmapheresis in the treatment of Guillain-Barré syndrome: A study from a tertiary care hospital from India.

Sanjay Vikrant1, Surinder Thakur2, Ashok Sharma2, Dalip Gupta2, Sudhir Sharma3.   

Abstract

BACKGROUND: Reports on therapeutic plasma exchange (TPE) with the standard hemodialysis equipment are scarce, particularly from developing countries.
MATERIALS AND METHODS: A retrospective analysis of safety and efficacy of membrane-based TPE with a standard hemodialysis equipment for the treatment of severe Guillain-Barré syndrome (GBS) was conducted.
RESULTS: A total of 120 TPE sessions were performed in 31 GBS patients over a period of 5½ years. Each patient underwent a mean of 3.8 ± 1.5 TPE sessions. One (3.2%) patient died. Thirty (96.8%) patients survived and recovered. At 2 weeks, there was a significant improvement in the grade of power in both the upper and lower extremities (P = 0.001) and a significant decrease in the GBS disability grade (P = 0.001). Twenty four (77.4%) patients were able to walk unaided. Complications observed were: hypotension in 12 (10%), accelerated hypertension in 3 (2.5%), chills and rigors in 5 (4.2%), bleeding in 5 (4.2%), and filter clotting in 6 (5%) sessions. One patient experienced an anaphylactoid reaction and 1 patient survived a cardiorespiratory arrest. Two patients developed aspiration pneumonia and 1 patient developed catheter site infection.
CONCLUSIONS: Membrane-based TPE can be conveniently delivered with the standard hemodialysis equipment. It is a safe, effective, and comparatively less expensive treatment option for GBS.

Entities:  

Mesh:

Year:  2017        PMID: 28488614     DOI: 10.4103/neuroindia.NI_907_15

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  1 in total

1.  Plasmapheresis: A Retrospective Audit of Procedures from a Tertiary Care Center in Southern India.

Authors:  O T Ahammed Nizar; Pratheeksha Rai; Shobhana Nayak Rao; M Pradeep Shenoy
Journal:  Indian J Crit Care Med       Date:  2017-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.